← All trials
NCT06465420
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 29, 2024
- Primary completion
- Dec 29, 2024
- Completion date
- Mar 31, 2025
- First posted
- Jun 18, 2024
- Last posted
- Jun 24, 2024
- Enrollment
- 30
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- InventVacc Biologicals Inc.Lead sponsor
- McGill UniversityOfficial
- Canadian Center for VaccinologyOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.